Research programme: aptamer-dicer substrate RNAi therapeutics - Archemix/Dicerna

Drug Profile

Research programme: aptamer-dicer substrate RNAi therapeutics - Archemix/Dicerna

Alternative Names: Aptamer-DsiRNA

Latest Information Update: 16 Nov 2012

Price : $50

At a glance

  • Originator Archemix Corporation; Dicerna Pharmaceuticals
  • Class Oligonucleotides; RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 16 Nov 2012 Discontinued for Undefined indication in USA (Parenteral)
  • 21 Jul 2009 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top